Drug: Niraparib (Zejula, Tesaro)
Status: Approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk in response to platinum-based chemotherapy
Significant Information:
- A poly(adenosine diphosphate–ribose) polymerase inhibitor that blocks an enzyme involved in repairing damaged DNA
- Patients were tested with an FDA-approved test to determine whether they had a